Acepodia Partners with Pfizer to Develop Antibody-Cell Conjugation-Based Cell Therapies for Autoimmune Disorders
Shots:
- Acepodia & Pfizer Ignite have partnered to advance antibody-cell conjugation-based cell therapies for autoimmune disorders, as per which the latter will offer strategic guidance & resources to Acepodia for the same
- The partnership will leverage Pfizer's resources & R&D capabilities in clinical trial design and regulatory strategies, enhancing drug development. Acepodia will hold on to all the rights of its program & future collaborations
- Pfizer Ignite will further support Acepodia's ACE1831, currently under P-I study for non-Hodgkin's lymphoma (NHL) & has shown a strong, lasting effect even at the lowest dose, as well as ACE2016 for solid tumors
Ref: PR Newswire | Image: Acepodia & Pfizer
Related News:- Acepodia Reports the US FDA Clearance of IND Application for ACE2016 to Treat Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
